Objective: To observe the efficacy and safety of combined admistration of betaxolol and brimonidine eyedrop in treatment of primary open angle glaucoma (POAG) and ocular hypertension (OHT).Methods:80 eyes of 48 individuals with POAG or OHT were randomly divided into three groups,receiving 0.5% betaxolol,0.2% brimonidine and 0.5% betaxolol combined with 0.2%brimonidine,twice daily respectively.The changes of intraocular pressure (IOP) were measured by non-contact tonometer (NCT) and documented before and 1,2,3 and 4 weeks after treatment.In addition,the side effects were also recorded throughout the treatment.Results:The IOPs after treatment were significantly reduced at all the time points compared with pre-treatment levels in each group.Patients receiving brimonidine had a greater reduction in IOP compared with their counterparts in the betaxolol group,however the difference was not statistically significant.The IOP declination was significantly larger in the combined therapy group than in the other two groups (P<0.01).Slight discomforts,such as sensation of foreign bodies,ocular irritation,dizziness,headache,fatigue,and dryness of mouth and nose were presented in several individuals,without leading to interruption of the therapy.No severe side effects were observed after the administration.Conclusion:Betaxolol combined with Brimonidine for treating the patients with primary open-angle glaucoma or ocular hypertension can effectively decrease IOPs without severe side effects.%目的：观察倍他洛尔和溴莫尼定联合治疗开角型青光眼和高眼压征的临床疗效和安全性。方法：将原发性开角型青光眼和高眼压征患者48例（80只眼），随机分为三组（倍他洛尔组、溴莫尼定组、溴莫尼定与倍他洛尔联合组）。倍他洛尔组按照0.5%倍他洛尔，溴莫尼定组按照0.2%溴莫尼定，溴莫尼定与倍他洛尔联合组按照0.5%倍他洛尔加0.2%溴莫尼定每天给药两次。观察治疗前和治疗1、2、3、4周后的降眼压作用及记录不良反应。结果：三组治疗4周后的眼压均有显著下降，与倍他洛尔组相比，溴莫尼定组眼压下降幅度稍大，但无显著统计学意义(P＞0.05)；倍他洛尔与溴莫尼定联合组眼压下降的幅度均高于倍他洛尔组与溴莫尼定组，且差异均具有显著统计学意义（P＜0.01）。在研究期间个别患者出现眼部异物感、刺激性、眩晕、头疼、疲劳、口鼻干燥等轻微不适症状，但未致患者退出试验。研究期间未见严重不良反应患者。结论：联合应用倍他洛尔和溴莫尼定对于开角型青光眼及高眼压征具有良好的降眼压疗效，且无严重不良反应。
展开▼
